This trial is active, not recruiting.

Condition cocaine dependence
Treatment [11c]-p943
Sponsor Yale University
Start date July 2014
End date August 2016
Trial size 30 participants
Trial identifier NCT02181491, 0811004457


There has been recent interest in the role of the 5-HT1B receptor as a possible modulating factor in cocaine dependence, certainly in preclinical models. The Yale Positron Emission Tomography (PET) Center has developed a novel 5-HT1B receptor antagonist radioligand, [11C]-P943, which has been validated in human studies. We hypothesize that the 5-HT1B receptor plays a key role in cocaine dependence. The long term goal of this project would be to study pharmacological manipulation of the 5-HT1B receptor as a potential molecular target for cocaine dependence.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Intervention model factorial assignment
Masking open label

Primary Outcomes

time frame: 1 week

Eligibility Criteria

Male or female participants from 18 years up to 50 years old.

Inclusion Criteria: 1. age 18 - 50 years 2. voluntary, written, informed consent 3. physically healthy by medical history, physical, neurological, ECG, and laboratory examinations 4. for females, non-lactating, no longer of child-bearing potential (or agree to practice effective contraception during the study), and a negative serum pregnancy (B-HCG) test 5. English speaking 6. No other major Axis DSM-IV diagnosis present, besides required as below Inclusion criteria for cocaine dependent: 1. DSM-IV criteria for Cocaine Abuse (305.60) or Cocaine Dependence (304.20) 2. recent street cocaine use 3. intravenous and/or smoked (crack/ freebase) use 4. positive urine toxicology screen for cocaine Inclusion criteria for healthy controls: 1. No current, or history of, any DSM-IV diagnosis 2. No first-degree relative with history of psychotic, mood, or anxiety disorder Exclusion Criteria: 1. medical contraindications to AMPT administration (e.g., known sensitivity/reaction to AMPT) 2. medical contraindications to MPH administration (e.g., history of cardiac problems, seizures, etc.) 3. drug or alcohol dependence (except nicotine) 4. a primary major DSM-IV psychiatric diagnosis (schizophrenia, bipolar disorder, etc.), unrelated to cocaine or pathological gambling 5. positive answers on the cardiac screening questionnaire that may place the subject at higher risk, as determined by cardiologist review of both the questionnaire responses and screening ECG 6. current use of psychotropic and/or potentially psychoactive prescription medication 7. physical or laboratory (B-HCG) evidence of pregnancy 8. clotting disorders or recent anticoagulant therapy 9. MRI-incompatible implants and other contraindications for MRI (i.e., aneurysm clip, metal fragments, internal electrical devices such as a cochlear implant, spinal cord stimulator or pacemaker) 10. history of claustrophobia or feeling of inability to lie still on his back for the PET or MRI scans 11. history of prior radiation exposure for research purposes within the past year such that participation in this study would place them over Radioactive Drug Research Committee (RDRC) limits for annual radiation exposure. This guideline is an effective dose of 5 rem received per year 12. donation or loss of 550 mL of blood or more (including plasmapheresis) or receipt of a transfusion of any blood product within 8 weeks prior to the first dose of study drug 13. use any prescription medications and/or over-the-counter medications, vitamins and/or herbal supplements within 2 weeks prior to study and for the duration of the study without approval from the study doctor 14. eat grapefruit or grapefruit products, and drink alcohol, and anything containing caffeine 3 days before study and during study 15. For CD subjects, < 1 year of cocaine dependence 16. Subjects with current, past, or anticipated exposure to radiation in the workplace

Additional Information

Principal investigator Robert Malison, MD
Trial information was received from ClinicalTrials.gov and was last updated in December 2015.
Information provided to ClinicalTrials.gov by Yale University.